Literature DB >> 6056555

Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250").

E Varga, L Tringer.   

Abstract

Mesh:

Substances:

Year:  1967        PMID: 6056555

Source DB:  PubMed          Journal:  Acta Med Acad Sci Hung        ISSN: 0001-5989


× No keyword cloud information.
  18 in total

Review 1.  The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).

Authors:  I Miklya
Journal:  Mol Psychiatry       Date:  2016-08-02       Impact factor: 15.992

2.  Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment.

Authors:  A Prasad; V Glover; B L Goodwin; M Sandler; M Signy; S E Smith
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 3.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

4.  (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.

Authors:  J Knoll; F Yoneda; B Knoll; H Ohde; I Miklya
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

5.  Deprenyl is metabolized to methamphetamine and amphetamine in man.

Authors:  G P Reynolds; J D Elsworth; K Blau; M Sandler; A J Lees; G M Stern
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

6.  The possible mechanisms of action of (-)deprenyl in Parkinson's disease.

Authors:  J Knoll
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

7.  L-deprenyl plus L-phenylalanine in the treatment of depression.

Authors:  W Birkmayer; P Riederer; W Linauer; J Knoll
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

8.  Absence of "cheese effect" during deprenyl therapy: some recent studies.

Authors:  M Sandler; V Glover; A Ashford; G M Stern
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

Review 9.  Dopamine and depression.

Authors:  A S Brown; S Gershon
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.